Radiation oncology (London, England) · 2025
Impact of frailty on outcomes of inpatient stereotactic radiosurgery for brain metastasis: a national readmission database analysis 2016-2020.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chan Ryan Wing Yuk, Wang Chien-Kai, Lo Wei-Lun, Yeh Tu-Hsueh, Savaraj Niramol, Feun Lynn G, Chen Shu-Mei
Аннотация
BACKGROUND: It is not clear how frailty may affect the outcomes of stereotactic radiosurgery (SRS) for brain metastasis. This study aimed to evaluate the impact of frailty on clinical outcomes in patients ≥ 60 years old who underwent SRS for brain metastasis from a population-based perspective.
MATERIALS AND METHODS: Data were extracted from the National Readmission Database (NRD), 2016 to 2020. Inclusion criteria were ≥ 60 years old with brain metastasis who underwent SRS. Frailty was assessed using the modified Frailty Index (mFI), derived from 11 clinical conditions. The primary outcomes were in-hospital mortality, length of hospital stay (LOS), total hospital costs, and 30-day and 90-day readmission rates. Logistic and linear regression models were used to assess the association between frailty and outcomes.
RESULTS: A total of 904 patients (mean age: 71 years, 53% male) were included, of which 17.5% were defined as frail. After adjusting for demographic, clinical, and hospital-related factors, frailty was significantly associated with increased in-hospital mortality (adjusted odds ratio [aOR] = 2.39, 95% confidence interval [CI]: 1.16-4.92), longer LOS (adjusted Beta [aBeta] = 2.61 days, 95% CI: 1.95-3.28), higher total costs (aBeta = $36.04 thousand USD, 95% CI: 28.84-43.23), and higher 30-day readmission rate (aOR = 1.47, 95% CI: 1.02-2.11).
CONCLUSION: Frailty independently predicts poorer outcomes in older adults undergoing SRS for brain metastasis, including higher mortality, longer hospital stays, increased hospital costs, and increased 30-day readmission rate. These findings highlight the importance of incorporating frailty-informed risk stratification and perioperative care planning to optimize patient outcomes.
TRIAL REGISTRATION NUMBER: Not applicable.
MATERIALS AND METHODS: Data were extracted from the National Readmission Database (NRD), 2016 to 2020. Inclusion criteria were ≥ 60 years old with brain metastasis who underwent SRS. Frailty was assessed using the modified Frailty Index (mFI), derived from 11 clinical conditions. The primary outcomes were in-hospital mortality, length of hospital stay (LOS), total hospital costs, and 30-day and 90-day readmission rates. Logistic and linear regression models were used to assess the association between frailty and outcomes.
RESULTS: A total of 904 patients (mean age: 71 years, 53% male) were included, of which 17.5% were defined as frail. After adjusting for demographic, clinical, and hospital-related factors, frailty was significantly associated with increased in-hospital mortality (adjusted odds ratio [aOR] = 2.39, 95% confidence interval [CI]: 1.16-4.92), longer LOS (adjusted Beta [aBeta] = 2.61 days, 95% CI: 1.95-3.28), higher total costs (aBeta = $36.04 thousand USD, 95% CI: 28.84-43.23), and higher 30-day readmission rate (aOR = 1.47, 95% CI: 1.02-2.11).
CONCLUSION: Frailty independently predicts poorer outcomes in older adults undergoing SRS for brain metastasis, including higher mortality, longer hospital stays, increased hospital costs, and increased 30-day readmission rate. These findings highlight the importance of incorporating frailty-informed risk stratification and perioperative care planning to optimize patient outcomes.
TRIAL REGISTRATION NUMBER: Not applicable.